Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 6/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 2/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4992491 | 0.93 | MAPT (0.40) | KMT2AALDH1A1HPGDMEN1L3MBTL1 | |
| SCHEMBL4985506 | 0.91 | KMT2A (0.50) | KMT2AALDH1A1L3MBTL1KDM4ELMNA | |
| SCHEMBL4992075 | 0.86 | CYP3A4 (0.53) | KMT2AALDH1A1MEN1KDM4EMAPT | |
| SCHEMBL4987011 | 0.85 | PKM (0.46) | KMT2AALDH1A1HPGDMEN1L3MBTL1 | |
| SCHEMBL4988175 | 0.85 | AKR1C3 (0.47) | KMT2AALDH1A1KDM4ELMNATSHR | |
| SCHEMBL4983067 | 0.83 | PKM (0.43) | KMT2AALDH1A1HPGDMEN1L3MBTL1 | |
| SCHEMBL4987187 | 0.83 | ALDH1A1 (0.46) | KMT2AALDH1A1HPGDMEN1KDM4E | |
| SCHEMBL4985355 | 0.79 | EPHX2 (0.37) | KMT2AALDH1A1L3MBTL1 | |
| SCHEMBL4986738 | 0.79 | HSP90AB1 (0.45) | KMT2AALDH1A1MEN1KDM4EMAPT | |
| SCHEMBL4986044 | 0.77 | FAAH (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | RENOVIS, INC. | 2008-02-14 | — | — | US | claimed |
| US-7297700-B2 | Bicycloheteroaryl compounds as P2X7 modulators and uses thereof | RENOVIS, INC. (US) | 2007-11-20 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039478-A1 | Bicycloheteroaryl Compounds as P2X7 Modulators and Uses Thereof | P2RX7, P2RX3, P2RX2 | KMT2A 4614/4885ALDH1A1 3640/4885HPGD 368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.